留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝硬化的诊断、分期及治疗原则

王宇 王民 张冠华 何福亮 欧晓娟 贾继东

王宇, 王民, 张冠华, 等. 肝硬化的诊断、分期及治疗原则[J]. 临床肝胆病杂志, 2021, 37(1): 17-21. DOI: 10.3969/j.issn.1001-5256.2021.01.004
引用本文: 王宇, 王民, 张冠华, 等. 肝硬化的诊断、分期及治疗原则[J]. 临床肝胆病杂志, 2021, 37(1): 17-21. DOI: 10.3969/j.issn.1001-5256.2021.01.004
WANG Y, WANG M, ZHANG GH, et al. Clinical di-agnosis, staging, and therapeutic principles of liver cirrhosis[J]. J Clin Hepatol, 2021, 37(1): 17-21. DOI: 10.3969/j.issn.1001-5256.2021.01.004
Citation: WANG Y, WANG M, ZHANG GH, et al. Clinical di-agnosis, staging, and therapeutic principles of liver cirrhosis[J]. J Clin Hepatol, 2021, 37(1): 17-21. DOI: 10.3969/j.issn.1001-5256.2021.01.004

肝硬化的诊断、分期及治疗原则

DOI: 10.3969/j.issn.1001-5256.2021.01.004
基金项目: 

首都临床特色应用研究与技术推广 Z171100001017037

国家科技重大专项 2017ZX10105015002

北京市医院管理局消化内科学科协同发展中心消化专项特色项目 XXT04

详细信息
    作者简介:

    王宇(1972—),男,主任医师,主要从事肝硬化及门脉高压的诊治及临床研究

    通讯作者:

    贾继东,jia_jd@ccmu.edu.cn

  • 作者贡献声明:王宇负责写作设计、搜集资料并分析,撰写论文;王民、张冠华、何福亮及欧晓娟参与搜集资料、修改论文;贾继东负责写作设计、思路指导及论文修改并最后定稿。
  • 中图分类号: R575.2

Clinical diagnosis, staging, and therapeutic principles of liver cirrhosis

  • 摘要: 近年来,随着对肝硬化的发病机制、病理生理、治疗和预后研究不断深入,国内外学者在诊断分期和治疗观念上有了很大变化。除了常用的代偿期和失代偿期二分法外,还可以根据腹水、食管胃静脉曲张出血及严重感染等表现分为五期。新的分期方法突出了不同阶段疾病的特点,为治疗提供了目标和依据。目前,病因治疗、针对关键发病机制和主要并发症的治疗,以及营养支持、运动指导及戒烟酒、改善口腔卫生等改善生活方式的综合治疗,是延缓疾病进展、改善预后的关键,而肝移植仍是治疗终末期肝硬化的最有效手段。
  • [1] TSOCHATZIS EA, BOSCH J, BURROUGHS AK. Liver cirrhosis[J]. Lancet, 2014, 383(9930): 1749-1761. DOI: 10.1016/S0140-6736(14)60121-5
    [2] Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425.(in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.11.006

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006
    [3] European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024
    [4] Chinese Society of Infectious Disease, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.12.007

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007
    [5] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C (2019 version) [J]. J Clin Hepatol, 2019, 35(12): 2670-2686. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.12.008

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008
    [6] Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association; Liver Disease Committee of Chinese Research Hospital Association. Consensus on clinical application of transient elastography detecting liver fibrosis: A 2018 update[J]. Chin J Hepatol, 2019, 27(3): 182-191. (in Chinese)

    中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27(3): 182-191.
    [7] WANG Y, WANG M, OU XJ, et al. Diagnosis and treatment of portal hypertension caused by rare diseases[J]. J Clin Hepatol, 2019, 35(1): 29-32. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.01.005

    王宇, 王民, 欧晓娟, 等. 少见、罕见疾病所致门静脉高压症的诊断与治疗[J]. 临床肝胆病杂志, 2019, 35(1): 29-32. DOI: 10.3969/j.issn.1001-5256.2019.01.005
    [8] FLEMING KM, AITHAL GP, CARD TR, et al. All-cause mortality in people with cirrhosis compared with the general population: A population-based cohort study[J]. Liver Int, 2012, 32(1): 79-84. DOI: 10.1111/j.1478-3231.2011.02517.x
    [9] D'AMICO G, GARCIA-TSAO G, PAGLIARO L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies[J]. J Hepatol, 2006, 44(1): 217-231. DOI: 10.1016/j.jhep.2005.10.013
    [10] ARVANITI V, D'AMICO G, FEDE G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J]. Gastroenterology, 2010, 139(4): 1246-1256, 1256. e1-e5. DOI: 10.1053/j.gastro.2010.06.019
    [11] FEDE G, D'AMICO G, ARVANITI V, et al. Renal failure and cirrhosis: A systematic review of mortality and prognosis[J]. J Hepatol, 2012, 56(4): 810-818. DOI: 10.1016/j.jhep.2011.10.016
    [12] D'AMICO G, MORABITO A, D'AMICO M, et al. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis[J]. Hepatol Int, 2018, 12(Suppl 1): 34-43. http://europepmc.org/abstract/MED/28681347
    [13] D'AMICO G, MORABITO A, D'AMICO M, et al. Clinical states of cirrhosis and competing risks[J]. J Hepatol, 2018, 68(3): 563-576. DOI: 10.1016/j.jhep.2017.10.020
    [14] KIM TY, LEE JG, SOHN JH, et al. Hepatic venous pressure gradient predicts long-term mortality in patients with decompensated cirrhosis[J]. Yonsei Med J, 2016, 57(1): 138-145. DOI: 10.3349/ymj.2016.57.1.138
    [15] GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906
    [16] SMITH A, BAUMGARTNER K, BOSITIS C. Cirrhosis: Diagnosis and management[J]. Am Fam Physician, 2019, 100(12): 759-770.
    [17] WONG VW, CHIM AM, WONG GL, et al. Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B[J]. Liver Transpl, 2007, 13(9): 1228-1235. DOI: 10.1002/lt.21222
    [18] LIAW YF, SUNG JJ, CHOW WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med, 2004, 351(15): 1521-1531. DOI: 10.1056/NEJMoa033364
    [19] GENTILE I, SCOTTO R, COPPOLA C, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: Results from an Italian real-life cohort (Liver Network Activity-LINA cohort)[J]. Hepatol Int, 2019, 13(1): 66-74. DOI: 10.1007/s12072-018-9914-6
    [20] HARMS MH, van BUUREN HR, CORPECHOT C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis[J]. J Hepatol, 2019, 71(2): 357-365. DOI: 10.1016/j.jhep.2019.04.001
    [21] LI YN, MA H, ZHOU L, et al. Autoimmune hepatitis-related cirrhosis: Clinical features and effectiveness of immunosuppressive treatment in Chinese patients[J]. Chin Med J (Engl), 2016, 129(20): 2434-2440. DOI: 10.4103/0366-6999.191760
    [22] YANG J, GE K, CHEN L, et al. The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective β-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of variceal rebleeding: A meta-analysis[J]. Eur J Gastroenterol Hepatol, 2019, 31(12): 1518-1526. DOI: 10.1097/MEG.0000000000001442
    [23] MOHANTY A, TATE JP, GARCIA-TSAO G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis[J]. Gastroenterology, 2016, 150(2): 430-440. e1. DOI: 10.1053/j.gastro.2015.10.007
    [24] BOSCH J, GRACIA-SANCHO J, ABRALDES JG. Cirrhosis as new indication for statins[J]. Gut, 2020, 69(5): 953-962. DOI: 10.1136/gutjnl-2019-318237
    [25] LI S, ZHANG C, LIN LL, et al. Early-TIPS versus current standard therapy for acute variceal bleeding in cirrhosis patients: A systemic review with meta-analysis[J]. Front Pharmacol, 2020, 11: 603. DOI: 10.3389/fphar.2020.00603
    [26] SONG T, RÖSSLE M, HE F, et al. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis[J]. Dig Liver Dis, 2018, 50(4): 323-330. DOI: 10.1016/j.dld.2018.01.123
    [27] BEST LM, FREEMAN SC, SUTTON AJ, et al. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: A network meta-analysis[J]. Cochrane Database Syst Rev, 2019, 9: CD013103. http://www.researchgate.net/publication/327452682_Treatment_for_hepatorenal_syndrome_in_people_with_decompensated_liver_cirrhosis_A_network_meta-analysis
    [28] SRIDHARAN K, SIVARAMAKRISHNAN G. Vasoactive agents for the management of variceal bleeding: A mixed treatment comparison network meta-analysis and trial sequential analysis of randomized clinical trials[J]. Drug Res (Stuttg), 2019, 69(9): 487-495. DOI: 10.1055/a-0846-3071
    [29] GE PS, RUNYON BA. Treatment of patients with cirrhosis[J]. N Engl J Med, 2016, 375(8): 767-777. DOI: 10.1056/NEJMra1504367
    [30] KROWKA MJ, FALLON MB, KAWUT SM, et al. International liver transplant society practice guidelines: Diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension[J]. Transplantation, 2016, 100(7): 1440-1452. DOI: 10.1097/TP.0000000000001229
    [31] XU X, GUO X, DE STEFANO V, et al. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis[J]. Hepatol Int, 2019, 13(4): 468-481. DOI: 10.1007/s12072-019-09951-6
    [32] ZHANG Y, XU BY, WANG XB, et al. Prevalence and clinical significance of portal vein thrombosis in patients with cirrhosis and acute decompensation[J]. Clin Gastroenterol Hepatol, 2020, 18(11): 2564-2572. e1. DOI: 10.1016/j.cgh.2020.02.037
    [33] CERINI F, GONZALEZ JM, TORRES F, et al. Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study[J]. Hepatology, 2015, 62(2): 575-583. DOI: 10.1002/hep.27783
    [34] ZANETTO A, RODRIGUEZ-KASTRO KI, GERMANI G, et al. Mortality in liver transplant recipients with portal vein thrombosis - an updated meta-analysis[J]. Transpl Int, 2018, 31(12): 1318-1329. DOI: 10.1111/tri.13353
    [35] INTAGLIATA NM, CALDWELL SH, TRIPODI A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis[J]. Gastroenterology, 2019, 156(6): 1582-1599. e1. DOI: 10.1053/j.gastro.2019.01.265
    [36] PETTINARI I, VUKOTIC R, STEFANESCU H, et al. Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis[J]. Am J Gastroenterol, 2019, 114(2): 258-266. DOI: 10.1038/s41395-018-0421-0
    [37] LOFFREDO L, PASTORI D, FARCOMENI A, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: A systematic review and Meta-analysis[J]. Gastroenterology, 2017, 153(2): 480-487. e1. DOI: 10.1053/j.gastro.2017.04.042
    [38] NORONHA FERREIRA C, REIS D, CORTEZ-PINTO H, et al. Anticoagulation in cirrhosis and portal vein thrombosis is safe and improves prognosis in advanced cirrhosis[J]. Dig Dis Sci, 2019, 64(9): 2671-2683. DOI: 10.1007/s10620-019-05572-z
    [39] PONZIANI FR, ZOCCO MA, CERRITO L, et al. Bacterial translocation in patients with liver cirrhosis: Physiology, clinical consequences, and practical implications[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(7): 641-656. http://europepmc.org/abstract/MED/29806487
    [40] SALEHI S, TRANAH TH, LIM S, et al. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list[J]. Aliment Pharmacol Ther, 2019, 50(4): 435-441. DOI: 10.1111/apt.15326
    [41] KANG SH, LEE YB, LEE JH, et al. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy[J]. Aliment Pharmacol Ther, 2017, 46(9): 845-855. DOI: 10.1111/apt.14275
    [42] BUNCHORNTAVAKUL C, REDDY KR. Review article: Malnutrition/sarcopenia and frailty in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2020, 51(1): 64-77. DOI: 10.1111/apt.15571
    [43] TANDON P, BERZIGOTTI A. Management of lifestyle factors in individuals with cirrhosis: A pragmatic review[J]. Semin Liver Dis, 2020, 40(1): 20-28. DOI: 10.1055/s-0039-1696639
  • 加载中
计量
  • 文章访问数:  282
  • HTML全文浏览量:  38
  • PDF下载量:  109
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-11-19
  • 修回日期:  2020-11-19
  • 刊出日期:  2021-01-18
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回